{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:39:42Z","timestamp":1769099982110,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013377","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000}}],"reference-count":101,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013377.pub2","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T12:55:16Z","timestamp":1710248116000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic vaccines for advanced non-small cell lung cancer"],"prefix":"10.1002","volume":"2024","author":[{"given":"Marcela","family":"Cort\u00e9s-Jofr\u00e9","sequence":"additional","affiliation":[{"name":"Faculty of Medicine; Universidad Cat\u00f3lica de la Sant\u00edsima Concepci\u00f3n; Concepci\u00f3n Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikel","family":"Rueda-Etxebarria","sequence":"additional","affiliation":[{"name":"Research in Sciences of dissemination and implementation in health services; Biobizkaia Health Research Institute; Barakaldo Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emeline","family":"Orillard","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; Besan\u00e7on France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Jimenez Tejero","sequence":"additional","affiliation":[{"name":"Independent Cochrane review author; Madrid Spain"},{"name":"Faculty of Medicine; Universidad Francisco de Vitoria; Pozuelo de Alarc\u00f3n Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Ram\u00f3n","family":"Rueda","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Public Health; Faculty of Medicine and Nursing. University of the Basque Country; Leioa Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"issue":"14","key":"10.1002\/14651858.CD013377.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"3660-71","DOI":"10.1158\/1078-0432.CCR-13-1674","article-title":"A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients","volume":"20","author":"Alfonso","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"10.1002\/14651858.CD013377.pub2-BIB0002|cit2","first-page":"1","article-title":"Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1","volume":"34","author":"Besse","year":"2023","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013377.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/s41416-020-0785-y","article-title":"Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial","volume":"122","author":"Gridelli","year":"2020","journal-title":"British Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD013377.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3390\/cancers13071658","article-title":"Clinical activity of an hTERT-specific cancer vaccine (Vx-001) in \"immune desert\" NSCLC","volume":"13","author":"Pateras","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Hernandez M Neninger E Ortiz RA Camacho K Amador RM Bello L Switch maintenance therapy with racotumomab or nimotuzumab versus docetaxel for NSCLC patients Annals of Oncology 2016 10.1093\/annonc\/mdw378.47","DOI":"10.1093\/annonc\/mdw378.47"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Hernandez M Neninger E Santiesteban E Camacho K Hernandez N Amador R Efficacy of racotumomab or nimotuzumab versus docetaxel as secondline therapy for advanced non-small cell lung cancer patients Annals of Oncology 2018 viii415 10.1093\/annonc\/mdy288.037","DOI":"10.1093\/annonc\/mdy288.037"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/GOS.1000230","article-title":"Safety and efficacy of racotumomab-alum orimotuzumab versus docetaxel as switch maintenance therapy for advanced non-small cell lung cancer patients: a phase III open label randomized non-inferiority trial","volume":"7","author":"Hern\u00e1ndez","year":"2021","journal-title":"Global Surgery"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Crombet T Neninger E Osorio M Catala M Torre A Leonard I Vaccination with epidermal growth factor (EGF) for non-small cell lung cancer (NSCLC) therapy: preliminary results from a randomized phase II clinical trial American Society of Clinical Oncology 2004 166","DOI":"10.1200\/jco.2004.22.90140.2514"},{"issue":"3","key":"10.1002\/14651858.CD013377.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"840-6","DOI":"10.1158\/1078-0432.CCR-07-1050","article-title":"Effective inhibition of the epidermal growth factor\/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine","volume":"14","author":"Garc\u00eda","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"10.1002\/14651858.CD013377.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1200\/JCO.2007.11.5980","article-title":"Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer","volume":"26","author":"Neninger","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013377.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"906-14","DOI":"10.1093\/annonc\/mdh220","article-title":"SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results","volume":"15","author":"O'Brien","year":"2004","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013377.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"1125-33","DOI":"10.1016\/S1470-2045(11)70259-5","article-title":"Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial","volume":"12","author":"Quoix","year":"2011","journal-title":"Lancet Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013377.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"e0132568","DOI":"10.1371\/journal.pone.0132568","article-title":"Impact of TG4010 vaccine on health-related quality of life in advanced non-small-cell lung cancer: results of a phase IIB clinical trial","volume":"10","author":"Rotonda","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1002\/14651858.CD013377.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"212-23","DOI":"10.1016\/S1470-2045(15)00483-0","article-title":"TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b\/3 trial","volume":"17","author":"Quoix","year":"2016","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Quoix E Nemunaitis J Papai Z Lena H Genet D Louis C TG4010 immunotherapy combined with first-line chemotherapy in advanced non-small cell lung cancer (NSCLC). Phase 2b results of the time study Annals of Oncology 2015 i29 10.1093\/annonc\/mdv050.9","DOI":"10.1093\/annonc\/mdv050.09"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Quoix E Sequist L Nemunaitis J Beck T Jaskiewicz P Oster JP TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study Journal of ImmunoTherapy of Cancer 2014 10.1002\/central\/CN-01472266\/full","DOI":"10.1186\/2051-1426-2-S3-O12"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Quoix EA Forget F Papai-Szekely Z Ottensmeier CH Nemunaitis JJ FElip E Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy Journal of Clinical Oncology 2015 10.1002\/central\/CN-01130326\/full","DOI":"10.1200\/jco.2015.33.15_suppl.3034"},{"issue":"1","key":"10.1002\/14651858.CD013377.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"7070","DOI":"10.1186\/s40425-017-0274-x","article-title":"Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC","volume":"5","year":"2017","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"15","key":"10.1002\/14651858.CD013377.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"3782-90","DOI":"10.1158\/1078-0432.CCR-15-0855","article-title":"A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients","volume":"22","author":"Rodriguez","year":"2016","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD013377.pub2-BIB0020|cit20","first-page":"69","article-title":"Quality of life assessment in patients with non-small cell lung cancer treated with CIMAvaxEGF vaccine","volume":"30","author":"Viada-Gonz\u00e1lez","year":"2021","journal-title":"VacciMonitor"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"1745108","DOI":"10.1155\/2016\/1745108","article-title":"Randomized phase II study of docetaxel plus personalized peptide vaccination versus docetaxel plus placebo for patients with previously treated advanced wild type EGFR non-small-cell lung cancer","volume":"2016","author":"Takayama","year":"2016","journal-title":"Journal of Immunological Research"},{"issue":"1","key":"10.1002\/14651858.CD013377.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"59-68","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial","volume":"15","author":"Butts","year":"2014","journal-title":"Lancet Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013377.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/annonc\/mdv104","article-title":"Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses","volume":"26","author":"Mitchell","year":"2015","journal-title":"Annals of Oncology"},{"issue":"2 Suppl 3","key":"10.1002\/14651858.CD013377.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"P82","DOI":"10.1186\/2051-1426-2-S3-P82","article-title":"A phase II study of viagenpumatucel-l (HS-110) in combination with low-dose cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer","volume":"6","author":"Cohen","year":"2014","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013377.pub2-BIB0025|cit25","first-page":"1","article-title":"NLG-0301: an open-label, randomized phase 2B active control study of second-line tergenpumatucel-L immunotherapy versus docetaxel in patients with progressive or relapsed non-small cell lung cancer (NSCLC)","volume":"32","author":"Govindan","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013377.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00262-018-2236-7","article-title":"Phase I\/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma","volume":"67","author":"Gray","year":"2018","journal-title":"Cancer Immunology Immunotherapy"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2017.01.007","article-title":"Phase I\/II study of tecemotide cancer immunotherapy for Japanese patients with unresectable stage III non-small cell lung cancer (NSCLC)","volume":"105","author":"Katakami","year":"2017","journal-title":"Lung Cancer"},{"issue":"15 suppl","key":"10.1002\/14651858.CD013377.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"TPS7608","DOI":"10.1200\/jco.2014.32.15_suppl.tps7608","article-title":"START2: tecemotide in unresectable stage III NSCLC after first-line concurrent chemoradiotherapy","volume":"32","author":"Ramalingam","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013377.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/JTO.0b013e31817c6b4f","article-title":"A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III\/IV Non-small cell lung cancer","volume":"3","author":"Ramlau","year":"2008","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fimmu.2017.00269","article-title":"CIMAvax-EGF: a new therapeutic vaccine for advanced non-small cell lung cancer patients","volume":"8","author":"Saavedra","year":"2017","journal-title":"Frontiers in Immunology"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0031|cit31","unstructured":"https:\/\/trialsearchwhoint\/?TrialID=RPCEC00000368 Evaluation of the immune response generated after vaccination with CIMAvax-EGF using different maintenance schedules Cuban registry of clinical trials"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1186\/1471-2407-14-748","article-title":"Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive\u00ae) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer","volume":"14","author":"Sebastian","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/1471-2407-11-430","article-title":"INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer","volume":"11","author":"Park","year":"2011","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1002\/14651858.CD013377.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"issue":"20","key":"10.1002\/14651858.CD013377.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD013377.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Villegas","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013377.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/2051-1426-3-S2-P428","article-title":"Safety data of montanide ISA 51 VG and montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines","volume":"3","author":"Ascarateil","year":"2015","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013377.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"59-68","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial","volume":"15","author":"Butts","year":"2014","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013377.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/s0895-4356(01)00477-2.","article-title":"What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592","volume":"55","author":"Cella","year":"2002","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0040|cit40","unstructured":"Covidence Veritas Health Innovation 2019"},{"issue":"1","key":"10.1002\/14651858.CD013377.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2191-1991-3-15","article-title":"Health-related quality of life questionnaires in lung cancer trials: a systematic literature review","volume":"3","author":"Damm","year":"2013","journal-title":"Health Economics Review"},{"issue":"26","key":"10.1002\/14651858.CD013377.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2015.66.3955","article-title":"The efficacy of tumor vaccines and cellular immunotherapies in non-small cell lung cancer: a systematic review and meta-analysis","volume":"34","author":"Dammeijer","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013377.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2217\/fon.13.166","article-title":"Immunotherapy for lung cancer: ongoing clinical trials","volume":"10","author":"Declerck","year":"2014","journal-title":"Future Oncology"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0044|cit44","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD013377.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jtcvs.2017.08.138","article-title":"The eighth edition TNM stage classification for lung cancer: what does it mean on main street?","volume":"15","author":"Detterbeck","year":"2018","journal-title":"Journal of Thoracic and Cardiovascular Surgery"},{"issue":"4","key":"10.1002\/14651858.CD013377.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s12032-014-0928-1","article-title":"Therapeutic vaccination for non-small-cell lung cancer: a meta-analysis","volume":"31","author":"Ding","journal-title":"Medical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013377.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2217\/imt.14.82","article-title":"Immunotherapy and lung cancer: current developments and novel targeted therapies","volume":"6","author":"Domingues","year":"2014","journal-title":"Immunotherapy"},{"issue":"7109","key":"10.1002\/14651858.CD013377.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD013377.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"22","key":"10.1002\/14651858.CD013377.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0051|cit51","unstructured":"Ferlay J Ervik M Lam F Laversanne M Colombet M Mery L Age-standardized rate (world) per 100 000, incidence, both sexes, in 2022: trachea, bronchus and lung GLOBOCAN 2024"},{"issue":"1","key":"10.1002\/14651858.CD013377.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","journal-title":"Journal of Thoracic Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013377.pub2-BIB0053|cit53","first-page":"1","article-title":"NLG-0301: an open-label, randomized phase 2B active control study of second-line tergenpumatucel-L immunotherapy versus docetaxel in patients with progressive or relapsed non-small cell lung cancer (NSCLC)","volume":"32","author":"Govindan","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0054|cit54","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"issue":"20","key":"10.1002\/14651858.CD013377.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analysis of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Statistics in Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013377.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.4049\/jimmunol.181.9.6625","article-title":"Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody","volume":"181","author":"Hernandez","year":"2008","journal-title":"Journal of Immunology (Baltimore, Md. 1950)"},{"issue":"6","key":"10.1002\/14651858.CD013377.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.4049\/jimmunol.1000609","article-title":"Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in non-small cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism","volume":"186","author":"Hernandez","year":"2011","journal-title":"Journal of Immunology (Baltimore, Md. 1950)"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0058|cit58","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0059|cit59","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0060|cit60","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0061|cit61","unstructured":"Higgins JP Eldridge S Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-016-0204-3","article-title":"Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen","volume":"5","author":"Hillman","year":"2017","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2017.01.007","article-title":"Phase I\/II study of tecemotide cancer immunotherapy for Japanese patients with unresectable stage III non-small cell lung cancer (NSCLC)","volume":"105","author":"Katakami","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0064|cit64","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated October 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD013377.pub2-BIB0065|cit65","first-page":"189","article-title":"Lung cancer: biology and treatment options","volume":"1856","author":"Lemjabbar-alaoui","year":"2015","journal-title":"Biochimica et Biophysica Acta"},{"issue":"16","key":"10.1002\/14651858.CD013377.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/jnci\/djt184","article-title":"MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells","volume":"105","author":"Leone","year":"2013","journal-title":"Journal of the National Cancer Institute"},{"issue":"11","key":"10.1002\/14651858.CD013377.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00520-010-1016-5","article-title":"Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials","volume":"19","author":"Maringwa","year":"2011","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases \u2013 elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Current Opinion in Immunology"},{"issue":"7","key":"10.1002\/14651858.CD013377.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013377.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/fon.15.309","article-title":"Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms","volume":"12","author":"Monteiro","year":"2016","journal-title":"Future Oncology"},{"issue":"14","key":"10.1002\/14651858.CD013377.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"268","DOI":"10.21037\/atm.2016.06.24","article-title":"Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting","volume":"4","author":"Mountzios","year":"2016","journal-title":"Annals of Translational Medicine"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0073|cit73","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD013377.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1053\/j.seminoncol.2015.05.003","article-title":"Cancer and the immune system: basic concepts and targets for intervention","volume":"42","author":"Pardoll","year":"2015","journal-title":"Seminars in Oncology"},{"issue":"21","key":"10.1002\/14651858.CD013377.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013377.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"140","DOI":"10.5306\/wjco.v9.i7.140","article-title":"Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patients","volume":"9","author":"Prasad","year":"2018","journal-title":"World Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0077|cit77","first-page":"212","article-title":"T64010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b\/3 trial","volume":"2","author":"Quoix","year":"2017","journal-title":"Lancet Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013377.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11864-017-0476-y","article-title":"Immune checkpoint inhibitor therapy: what line of therapy and how to choose?","volume":"18","author":"Ramamurthy","year":"2017","journal-title":"Current Treatment Options in Oncology"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"issue":"19","key":"10.1002\/14651858.CD013377.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.lungcan.2017.02.002","article-title":"Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: current status and future approaches","volume":"106","author":"Remon","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0082|cit82","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"issue":"2","key":"10.1002\/14651858.CD013377.pub2-BIB0083|cit83","first-page":"70","article-title":"A new era of cancer immunotherapy: converting theory to performance","volume":"49","author":"Rosenberg","year":"1999","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"5","key":"10.1002\/14651858.CD013377.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/sim.2971","article-title":"Arcsine test for publication bias in meta-analyses with binary outcomes","volume":"27","author":"R\u00fccker","year":"2008","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013377.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00262-015-1773-6","article-title":"Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients","volume":"65","author":"Saavedra","year":"2016","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fimmu.2017.00269","article-title":"CIMAvax-EGF: a new therapeutic vaccine for advanced non-small cell lung cancer patients","volume":"8","author":"Saavedra","year":"2017","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"10.1002\/14651858.CD013377.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.vaccine.2016.12.020","article-title":"Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defence against tumors","volume":"35","author":"Schaedler","year":"2017","journal-title":"Vaccine"},{"issue":"6024","key":"10.1002\/14651858.CD013377.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0089|cit89","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"issue":"3","key":"10.1002\/14651858.CD013377.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s11136-013-0534-2","article-title":"Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy\u2013General (FACT-G)","volume":"23","author":"Smith","year":"2014","journal-title":"Quality of Life Research"},{"issue":"2","key":"10.1002\/14651858.CD013377.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4161\/hv.26919","article-title":"Recent advances in immunotherapy for non-small-cell lung cancer","volume":"10","author":"Suzuki","year":"2014","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"1","key":"10.1002\/14651858.CD013377.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40425-017-0274-x","article-title":"Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC","volume":"5","author":"Tosch","year":"2017","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annual Review of Immunology"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12105","article-title":"Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy","volume":"1284","author":"Vesely","year":"2013","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD013377.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"e006321","DOI":"10.1136\/bmjopen-2014-006321","article-title":"Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis","volume":"5","author":"Wang","year":"2015","journal-title":"BMJ Open"},{"issue":"1","key":"10.1002\/14651858.CD013377.pub2-BIB0097|cit97","first-page":"1","article-title":"Immunotherapy for lung cancer: advances and prospects","volume":"5","author":"Yang","year":"2016","journal-title":"American Journal of Clinical and Experimental Immunology"},{"key":"10.1002\/14651858.CD013377.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"32020","DOI":"10.1038\/srep32020","article-title":"The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis","volume":"6","author":"Zhou","year":"2016","journal-title":"Scientific Reports"},{"issue":"12","key":"10.1002\/14651858.CD013377.pub2-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011300.pub2","article-title":"Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent","author":"Zhu","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD013377.pub2-BIB0100|cit100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011300.pub3","article-title":"Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent","author":"Zhu","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013377.pub2-BIB0101|cit101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013377","article-title":"Therapeutic vaccines for advanced non-small cell lung cancer","author":"Cort\u00e9s-Jofr\u00e9","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:12:18Z","timestamp":1744589538000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013377.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Lung Cancer Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":101,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013377.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]}}}